Discovery Laboratories announced its launch of Surfaxin (lucinactant) Intratracheal Suspension for the prevention of respiratory distress syndrome (RDS) in premature infants at high-risk for RDS.
Infants with RDS often required animal-derived surfactant replacement therapy along with mechanical ventilation to survive. Surfaxin is the first synthetic, peptide-containing surfactant, and the only alternative to animal-derived surfactants currently available.
Endogenous pulmonary surfactant lowers surface tension at the air-liquid interface of the alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Surfaxin compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants.
Surfaxin Intratracheal Suspension is supplied as a 8.5mL sterile suspension in single-use vials.
For more information call (215) 488-9300 or visit Surfaxin.com.